Photocure granted Ipsen exclusive rights to commercialize Hexvix, an imaging agent used to diagnose bladder cancer, outside of the U.S. and the Nordic region

Photocure ASA

Norway / Small-Cap Biopharma (<$1 billion)

$138.5m on 10/14/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ipsen Group

France / Mid-Cap Biopharma ($1-$50 billion)

$2,683.3m on 10/14/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced